Literature DB >> 27738887

Dopamine D2 receptor expression in the corticotroph cells of the human normal pituitary gland.

Rosario Pivonello1,2, Marlijn Waaijers3, Johan M Kros4, Claudia Pivonello5, Cristina de Angelis6, Alessia Cozzolino5, Annamaria Colao5, Steven W J Lamberts3, Leo J Hofland3.   

Abstract

The dopamine D2 receptor is the main dopamine receptor expressed in the human normal pituitary gland. The aim of the current study was to evaluate dopamine D2 receptor expression in the corticotroph cell populations of the anterior lobe and pars intermedia, as well as posterior lobe of the human normal pituitary gland by immunohistochemistry. Human normal pituitary gland samples obtained from routine autopsies were used for the study. In all cases, histology together with immunostaining for adrenocorticotropic hormone, melanocyte-stimulating hormone, prolactin, and neurofilaments were performed and compared to the immunostaining for D2 receptor. D2 receptor was heterogeneously expressed in the majority of the cell populations of the anterior and posterior lobe as well as in the area localized between the anterior and posterior lobe, and arbitrary defined as "intermediate zone". This zone, characterized by the presence of nerve fibers included the residual pars intermedia represented by the colloid-filled cysts lined by the remnant melanotroph cells strongly expressing D2 receptors, and clusters of corticotroph cells, belonging to the anterior lobe but localized within the cysts and adjacent to the posterior lobe, variably expressing D2 receptors. D2 dopamine receptor is expressed in the majority of the cell populations of the human normal pituitary gland, and particularly, in the different corticotroph cell populations localized in the anterior lobe and the intermediate zone of the pituitary gland.

Entities:  

Keywords:  ACTH; Corticotroph cells; Cushing’s syndrome; Dopamine agonists; Dopamine receptors; Pituitary

Mesh:

Substances:

Year:  2016        PMID: 27738887     DOI: 10.1007/s12020-016-1107-2

Source DB:  PubMed          Journal:  Endocrine        ISSN: 1355-008X            Impact factor:   3.633


  57 in total

1.  Dopamine receptor expression and function in clinically nonfunctioning pituitary tumors: comparison with the effectiveness of cabergoline treatment.

Authors:  Rosario Pivonello; Carmela Matrone; Mariagiovanna Filippella; Luigi M Cavallo; Carolina Di Somma; Paolo Cappabianca; Annamaria Colao; Lucio Annunziato; Gaetano Lombardi
Journal:  J Clin Endocrinol Metab       Date:  2004-04       Impact factor: 5.958

2.  Dopaminergic receptors in the anterior pituitary gland. Correlation of [3H]dihydroergocryptine binding with the dopaminergic control of prolactin release.

Authors:  M G Caron; M Beaulieu; V Raymond; B Gagné; J Drouin; R J Lefkowitz; F Labrie
Journal:  J Biol Chem       Date:  1978-04-10       Impact factor: 5.157

Review 3.  Regulation of proopiomelanocortin gene expression in pituitary.

Authors:  J R Lundblad; J L Roberts
Journal:  Endocr Rev       Date:  1988-02       Impact factor: 19.871

Review 4.  Role of dopamine receptors in normal and tumoral pituitary corticotropic cells and adrenal cells.

Authors:  Mara Boschetti; Federico Gatto; Marica Arvigo; Daniela Esposito; Alberto Rebora; Miryam Talco; Manuela Albertelli; Elena Nazzari; Umberto Goglia; Francesco Minuto; Diego Ferone
Journal:  Neuroendocrinology       Date:  2010-09-10       Impact factor: 4.914

5.  The medical treatment of Cushing's disease: effectiveness of chronic treatment with the dopamine agonist cabergoline in patients unsuccessfully treated by surgery.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Paolo Cappabianca; Monica De Leo; Antongiulio Faggiano; Gaetano Lombardi; Leo J Hofland; Steven W J Lamberts; Annamaria Colao
Journal:  J Clin Endocrinol Metab       Date:  2008-10-28       Impact factor: 5.958

6.  Each individual isoform of the dopamine D2 receptor protects from lactotroph hyperplasia.

Authors:  Daniela Radl; Claudia De Mei; Eric Chen; Hyuna Lee; Emiliana Borrelli
Journal:  Mol Endocrinol       Date:  2013-04-22

7.  Evidence that hypothalamic periventricular dopamine neurons innervate the intermediate lobe of the rat pituitary.

Authors:  J L Goudreau; S E Lindley; K J Lookingland; K E Moore
Journal:  Neuroendocrinology       Date:  1992-07       Impact factor: 4.914

8.  Apomorphine injection stimulates beta-endorphin, adrenocorticotropin, and cortisol release in healthy man.

Authors:  D Jezova; M Vigas
Journal:  Psychoneuroendocrinology       Date:  1988       Impact factor: 4.905

Review 9.  Cushing's Syndrome.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Gaetano Lombardi; Annamaria Colao
Journal:  Endocrinol Metab Clin North Am       Date:  2008-03       Impact factor: 4.741

10.  The dopamine receptor in the intermediate lobe of the rat pituitary gland: pharmacological characterization.

Authors:  M Munemura; T E Cote; K Tsuruta; R L Eskay; J W Kebabian
Journal:  Endocrinology       Date:  1980-12       Impact factor: 4.736

View more
  10 in total

Review 1.  Medical Treatment of Cushing's Disease: An Overview of the Current and Recent Clinical Trials.

Authors:  Rosario Pivonello; Rosario Ferrigno; Maria Cristina De Martino; Chiara Simeoli; Nicola Di Paola; Claudia Pivonello; Livia Barba; Mariarosaria Negri; Cristina De Angelis; Annamaria Colao
Journal:  Front Endocrinol (Lausanne)       Date:  2020-12-08       Impact factor: 5.555

2.  Dopamine agonist-responsive Cushing's disease.

Authors:  Gurpreet Anand; Andrea Bink; Felix Beuschlein; Christoph Schmid
Journal:  BMJ Case Rep       Date:  2019-02-13

Review 3.  Diabetes in Cushing Disease.

Authors:  G Mazziotti; A M Formenti; S Frara; F Maffezzoni; M Doga; A Giustina
Journal:  Curr Diab Rep       Date:  2017-05       Impact factor: 4.810

4.  TSH and PRL, side-effect markers in aripiprazole treatment: adjunctive aripiprazole-induced thyrotropin oversuppression in a young man with schizophrenia.

Authors:  Hidenobu Ohta; Satoru Inoue; Koichiro Hara; Akihiko Watanabe
Journal:  BMJ Case Rep       Date:  2017-08-22

5.  Pituitary corticotroph identity and receptor-mediated signaling: a transcriptomics perspective.

Authors:  Stanko S Stojilkovic; Rafael M Previde; Arthur S Sherman; Patrick A Fletcher
Journal:  Curr Opin Endocr Metab Res       Date:  2022-06-09

6.  Dopaminergic, Noradrenergic, Adrenal, and Thyroid Abnormalities in Psychotic and Affective Disorders.

Authors:  Fabrice Duval; Marie-Claude Mokrani; Alexis Erb; Vlad Danila; Felix Gonzalez Lopera; Ludovic Jeanjean
Journal:  Front Psychiatry       Date:  2020-09-18       Impact factor: 4.157

7.  Dopamine Function and Hypothalamic-Pituitary-Thyroid Axis Activity in Major Depressed Patients with Suicidal Behavior.

Authors:  Fabrice Duval; Marie-Claude Mokrani; Vlad Danila; Alexis Erb; Felix Gonzalez Lopera; Mihaela Tomsa
Journal:  Brain Sci       Date:  2022-05-10

Review 8.  Diabetes Mellitus Secondary to Cushing's Disease.

Authors:  Mattia Barbot; Filippo Ceccato; Carla Scaroni
Journal:  Front Endocrinol (Lausanne)       Date:  2018-06-05       Impact factor: 5.555

Review 9.  Resistance to Dopamine Agonists in Pituitary Tumors: Molecular Mechanisms.

Authors:  Claudia Pivonello; Roberta Patalano; Mariarosaria Negri; Rosa Pirchio; Annamaria Colao; Rosario Pivonello; Renata Simona Auriemma
Journal:  Front Endocrinol (Lausanne)       Date:  2022-01-12       Impact factor: 5.555

Review 10.  The dopaminergic control of Cushing's syndrome.

Authors:  R Pivonello; C Pivonello; C Simeoli; M C De Martino; A Colao
Journal:  J Endocrinol Invest       Date:  2022-04-23       Impact factor: 5.467

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.